Short answer
IDEAYA Biosciences, Inc. (IDYA) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
IDEAYA Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
- Investor focus: cash position, operating expenses, pipeline progress, and development funding runway
Item EX-99.1 · Exhibit EX-99.1
- OptimUM-02 met its primary endpoint: median PFS 6.9 months versus 3.1 months, HR 0.42, p<0.0001
- NDA filing for darovasertib combination underway through FDA’s RTOR program, with completion expected in H2 2026
- Cash, equivalents and marketable securities $1.24B at June 30, 2026, supporting runway into 2030
- June financing raised $323.4M net from 7,222,225 shares and warrants for 5,555,576 shares
- Q2 net loss $112.5M, including R&D expense $108.7M and G&A expense $22.5M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IDEAYA Biosciences, Inc. 8-K filings
Get the next IDYA 8-K as it lands
Follow IDYA for push alerts, or ask the research agent what this filing means.